Fractyl Health's Q3 net loss narrows as costs fall, shifts focus to Revita
Overview
US metabolic therapeutics firm's Q3 net loss narrowed from prior year on lower operating expenses
Company announced plans to cut workforce by 45% and discontinue internal Rejuva development to focus on Revita in October
Positive six-month pivotal trial results for Revita; FDA De Novo submission planned for late Q4 2026
Outlook
Fractyl plans FDA De Novo submission for Revita in late Q4 2026
Company expects topline 12-month REMAIN-1 Pivotal Cohort data in Q1 2027
Fractyl expects quarterly operating cash spending to fall to about $8 mln by end-Q2 2027
Result Drivers
POSITIVE TRIAL RESULTS - REMAIN-1 met its six-month co-primary endpoint for weight loss retention after GLP-1 discontinuation with high statistical significance
CASH POSITION - As of September 30, Fractyl had approximately $31.5 million in cash and cash equivalents
CAPITAL - Co expects capital to be sufficient to fund planned De Novo submission and upcoming 12-month pivotal data
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | $14.2 mln | ||
Q3 Adjusted EBITDA | -$16 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Fractyl Health, Inc. is $39.00, about 4,325.8% above its November 11 closing price of $0.88
Reuters Recommended Reads
Nov 10 - Liquidia Q3 loss widens on litigation charge, negating Yutrepia demand
Nov 12 - Altimmune posts higher than expected Q3 loss
Nov 12 - Century Therapeutics Q3 net loss narrows, beats analyst expectations
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)